Sanofi Reports Positive but Mixed Phase 3 Results for Amlitelimab in Atopic Dermatitis with OX40L Targeting and Kaposi's Sarcoma Case
Sanofi Reports Positive but Mixed Phase 3 Results for Amlitelimab in Atopic Dermatitis with OX40L Targeting and Kaposi's Sarcoma Case
Sanofi announced positive Phase 3 results from COAST 1, COAST 2, and SHORE studies for amlitelimab, an anti-OX40 ligand antibody, showing improvements in skin clearance and itch reduction in moderate-to-severe atopic dermatitis patients aged 12+ compared to placebo. 1 2 3 COAST 1 met primary and key secondary endpoints (vIGA-AD 0/1, EASI-75, PP-NRS ≥4); COAST 2 met primary but mixed secondaries (EASI-75 and PP-NRS significant, vIGA-AD not); SHORE met all endpoints with topical therapies. 2 3 5 Data indicate progressive efficacy without plateau at Week 24, supporting Q12W dosing potential; long-term Atlantis Phase 2 data showed continued improvements to Week 52. 2 3 5 6 Results described as mixed by some analysts, falling short of Dupixent benchmarks despite meeting endpoints. 5 One patient with risk factors developed cutaneous Kaposi's sarcoma in Atlantis study, stopped treatment, and is recovering; well-tolerated overall. 5 Sources: 1. https://www.marketscreener.com/ne...
- Get link
- X
- Other Apps